Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Thymogen

Glu-Trp, EW dipeptide, Oglufanide, L-Glutamyl-L-tryptophan

Quick Stats
Studies 94
Trials 51
Score 2
2000 pubmed

Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats.

Anisimov. V N VN; Khavinson. V K VK; Morozov. V G VG

Key Findings

  • Maximum lifespan increased by about 100 days in treated rats
  • Overall tumor incidence was 1.5‑times lower, with malignant tumors 1.7‑times lower and blood‑cell cancers 3.4‑times lower
  • The calculated aging rate (Gompertz alpha) was reduced, indicating slower aging

Practical Outcomes

  • The results suggest Thymogen might have anti‑aging and anti‑cancer potential, but the study was limited to subcutaneous injections in rats. There’s no human dosing or safety data, so it isn’t ready for DIY use; it mainly points to a promising area for further clinical research.

Summary

In a rat study, regular injections of the synthetic peptide L‑Glu‑L‑Trp (Thymogen) slowed the biological aging process and cut down the number of spontaneous cancers, leading to a modest increase in the longest-lived animals.

Abstract

Immunomodulatory molecule L-Glu-L-Trp was isolated from natural calf thymic peptide complex Thymalin by reverse-phase high performance liquid chromatography. On the basis of the synthesized dipeptide a pharmaceutical was designed containing this compound, which later receives the brand name Thymogen. The agent activated T-cell differentiation, T-cell recognition of peptide-MHC complexes, induced changes in intracellular composition of cyclic nucleotides, and activated neutrophilic chemotaxis and phagocytosis. The effect of dipeptide on survival, life span and spontaneous tumor development was studied in female rats. Seventy-six, five-month-old outbred female rats were randomly subdivided into two groups and were subcutaneously injected with 0.2 ml of normal saline (controls, 32 rats) or with 5 micrograms/rat of the dipeptide L-Glu-L-Trp, dissolved in 0.2 ml of saline (44 rats), 5 times per week for 12 months. Animals were monitored up to their natural death and all the tumors discovered were studied microscopically. Mean life span of rats in both groups was similar but that of 10% maximum survived control rats constituted 949 +/- 16.1 days, whereas in the dipeptide-treated rats this value was 1048 +/- 21.1 days (P < 0.001). Six out of 44 rats treated with the drug survived over the maximum life span of control rats (965 days). The aging rate indicated as alpha in the Gompertz equation, was 0.0071 days-1 in controls and 0.0041 days-1 in rats exposed to L-Glu-L-Trp. Total tumor incidence was 1.5 times lower (P < 0.01), malignant tumor incidence 1.7 times lower (P < 0.01), and hematopoietic malignancies (leukemias and lymphomas) 3.4 times lower (P < 0.02) in rats exposed to the dipeptide in comparison with controls. Thus, treatment with L-Glu-L-Trp delayed aging rate and decreased spontaneous tumor incidence in rats.

Study Information

Provider

pubmed

Year

2000

DOI

10.1023/a:1010042008969